InvestorsHub Logo
Followers 32
Posts 4250
Boards Moderated 0
Alias Born 07/25/2007

Re: Protector post# 267379

Sunday, 06/26/2016 2:46:24 PM

Sunday, June 26, 2016 2:46:24 PM

Post# of 346386

vimantoo, you are missing your own point here. We were not talking about the PD-1/PD-L1. We were talking about 10+ PS receptor drugs to COMBINE with PD-1/PD-L1 vesus PS target (Bavituximab) one drug to combine with PD-1/PD-L1.

So your reply is besides the point because I never said the PD-1/PD-L1 doesn't work. BMY/Merck and others proved otherwise.



You kept claiming that the anti+PS antibody approach, specifically Bavi, is equivalent to using a combination of 10-12 anti-receptor/ligand antibodies. There is nothing to support that view as Bavi has failed repeatedly as a single agent or with chemo whereas single agent anti-receptors or anti-ligand approaches have worked well enough to merit FDA approval. The limited clinical trial data using combinations of two of such anti-receptor or anti-ligand approaches have showed synergistic improvements.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News